Global Oral Factor Xa Inhibitors Market Growth 2026-2032
The global Oral Factor Xa Inhibitors market size is predicted to grow from US$ 23480 million in 2025 to US$ 35570 million in 2032; it is expected to grow at a CAGR of 6.2% from 2026 to 2032.
Oral Factor Xa inhibitors are a class of anticoagulant medications that prevent blood clot formation by directly blocking Factor Xa, an enzyme crucial to the clotting process. Taken orally, these drugs are used to manage and prevent conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).Key examples include rivaroxaban, apixaban, and edoxaban.
The market for oral Factor Xa inhibitors has been expanding due to their advantages over traditional anticoagulants. Drugs such as rivaroxaban, apixaban, and edoxaban are increasingly favored for their ease of use, fixed dosing, and reduced need for monitoring, leading to their widespread adoption for managing conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).
Innovation and competition are driving the market, with pharmaceutical companies focusing on developing new formulations and extended-release versions. These advancements aim to enhance efficacy, safety profiles, and patient convenience. The growing range of options is contributing to a more dynamic market, offering healthcare providers more choices for anticoagulant therapy.
Despite the growth, the market faces challenges such as high costs and the introduction of alternative therapies. Regulatory changes and evolving treatment guidelines can also impact market trends. However, ongoing research and development are likely to sustain market momentum, as new drug options and improved formulations continue to emerge.
LP Information, Inc. (LPI) ' newest research report, the “Oral Factor Xa Inhibitors Industry Forecast” looks at past sales and reviews total world Oral Factor Xa Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Factor Xa Inhibitors sales for 2026 through 2032. With Oral Factor Xa Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Factor Xa Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Oral Factor Xa Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Factor Xa Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Factor Xa Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Factor Xa Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Factor Xa Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Factor Xa Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Oral Factor Xa inhibitors are a class of anticoagulant medications that prevent blood clot formation by directly blocking Factor Xa, an enzyme crucial to the clotting process. Taken orally, these drugs are used to manage and prevent conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).Key examples include rivaroxaban, apixaban, and edoxaban.
The market for oral Factor Xa inhibitors has been expanding due to their advantages over traditional anticoagulants. Drugs such as rivaroxaban, apixaban, and edoxaban are increasingly favored for their ease of use, fixed dosing, and reduced need for monitoring, leading to their widespread adoption for managing conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation (AF).
Innovation and competition are driving the market, with pharmaceutical companies focusing on developing new formulations and extended-release versions. These advancements aim to enhance efficacy, safety profiles, and patient convenience. The growing range of options is contributing to a more dynamic market, offering healthcare providers more choices for anticoagulant therapy.
Despite the growth, the market faces challenges such as high costs and the introduction of alternative therapies. Regulatory changes and evolving treatment guidelines can also impact market trends. However, ongoing research and development are likely to sustain market momentum, as new drug options and improved formulations continue to emerge.
LP Information, Inc. (LPI) ' newest research report, the “Oral Factor Xa Inhibitors Industry Forecast” looks at past sales and reviews total world Oral Factor Xa Inhibitors sales in 2025, providing a comprehensive analysis by region and market sector of projected Oral Factor Xa Inhibitors sales for 2026 through 2032. With Oral Factor Xa Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oral Factor Xa Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Oral Factor Xa Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oral Factor Xa Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Oral Factor Xa Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oral Factor Xa Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oral Factor Xa Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Oral Factor Xa Inhibitors market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Rivaroxaban
- Edoxaban
- Apixaban
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- Bristol Myers Squibb
- Daiichi Sankyo
- Janssen Pharmaceuticals
- Bayer
- Mylan
- Zydus
- Lupin
- Apotex
- Accord Healthcare
- Chia Tai Tianqing Pharmaceutical
- Shanghai Huilun Pharmaceutical
- Qilu Pharmaceutical
- HEC Pharma
- Cspc Ouyi Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Hansoh Pharma
- Huahai Pharmaceutical
- Yangtze River Pharmaceutical
- What is the 10-year outlook for the global Oral Factor Xa Inhibitors market?
- What factors are driving Oral Factor Xa Inhibitors market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Oral Factor Xa Inhibitors market opportunities vary by end market size?
- How does Oral Factor Xa Inhibitors break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Factor Xa Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Oral Factor Xa Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Oral Factor Xa Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Oral Factor Xa Inhibitors Segment by Type
2.2.1 Rivaroxaban
2.2.2 Edoxaban
2.2.3 Apixaban
2.2.4 Oral Factor Xa Inhibitors Sales by Type
2.2.4.1 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global Oral Factor Xa Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Oral Factor Xa Inhibitors Sale Price by Type (2021-2026)
2.3 Oral Factor Xa Inhibitors Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Oral Factor Xa Inhibitors Sales by Application
2.3.5.1 Global Oral Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
2.3.5.2 Global Oral Factor Xa Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Oral Factor Xa Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Oral Factor Xa Inhibitors Breakdown Data by Company
3.1.1 Global Oral Factor Xa Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Oral Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Oral Factor Xa Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Oral Factor Xa Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Oral Factor Xa Inhibitors Sale Price by Company
3.4 Key Manufacturers Oral Factor Xa Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Factor Xa Inhibitors Product Location Distribution
3.4.2 Players Oral Factor Xa Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORAL FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Oral Factor Xa Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Oral Factor Xa Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Oral Factor Xa Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Oral Factor Xa Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Oral Factor Xa Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Oral Factor Xa Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Factor Xa Inhibitors Sales Growth
4.4 APAC Oral Factor Xa Inhibitors Sales Growth
4.5 Europe Oral Factor Xa Inhibitors Sales Growth
4.6 Middle East & Africa Oral Factor Xa Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Oral Factor Xa Inhibitors Sales by Country
5.1.1 Americas Oral Factor Xa Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
5.2 Americas Oral Factor Xa Inhibitors Sales by Type (2021-2026)
5.3 Americas Oral Factor Xa Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Factor Xa Inhibitors Sales by Region
6.1.1 APAC Oral Factor Xa Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Oral Factor Xa Inhibitors Revenue by Region (2021-2026)
6.2 APAC Oral Factor Xa Inhibitors Sales by Type (2021-2026)
6.3 APAC Oral Factor Xa Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Factor Xa Inhibitors by Country
7.1.1 Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
7.2 Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026)
7.3 Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Factor Xa Inhibitors by Country
8.1.1 Middle East & Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Factor Xa Inhibitors
10.3 Manufacturing Process Analysis of Oral Factor Xa Inhibitors
10.4 Industry Chain Structure of Oral Factor Xa Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Factor Xa Inhibitors Distributors
11.3 Oral Factor Xa Inhibitors Customer
12 WORLD FORECAST REVIEW FOR ORAL FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Oral Factor Xa Inhibitors Market Size Forecast by Region
12.1.1 Global Oral Factor Xa Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Oral Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Oral Factor Xa Inhibitors Forecast by Type (2027-2032)
12.7 Global Oral Factor Xa Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.5.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Mylan
13.6.1 Mylan Company Information
13.6.2 Mylan Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.6.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Mylan Main Business Overview
13.6.5 Mylan Latest Developments
13.7 Zydus
13.7.1 Zydus Company Information
13.7.2 Zydus Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.7.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zydus Main Business Overview
13.7.5 Zydus Latest Developments
13.8 Lupin
13.8.1 Lupin Company Information
13.8.2 Lupin Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.8.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lupin Main Business Overview
13.8.5 Lupin Latest Developments
13.9 Apotex
13.9.1 Apotex Company Information
13.9.2 Apotex Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.9.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Apotex Main Business Overview
13.9.5 Apotex Latest Developments
13.10 Accord Healthcare
13.10.1 Accord Healthcare Company Information
13.10.2 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.10.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Accord Healthcare Main Business Overview
13.10.5 Accord Healthcare Latest Developments
13.11 Chia Tai Tianqing Pharmaceutical
13.11.1 Chia Tai Tianqing Pharmaceutical Company Information
13.11.2 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.11.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.11.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.12 Shanghai Huilun Pharmaceutical
13.12.1 Shanghai Huilun Pharmaceutical Company Information
13.12.2 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.12.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Huilun Pharmaceutical Main Business Overview
13.12.5 Shanghai Huilun Pharmaceutical Latest Developments
13.13 Qilu Pharmaceutical
13.13.1 Qilu Pharmaceutical Company Information
13.13.2 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.13.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Qilu Pharmaceutical Main Business Overview
13.13.5 Qilu Pharmaceutical Latest Developments
13.14 HEC Pharma
13.14.1 HEC Pharma Company Information
13.14.2 HEC Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.14.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 HEC Pharma Main Business Overview
13.14.5 HEC Pharma Latest Developments
13.15 Cspc Ouyi Pharmaceutical
13.15.1 Cspc Ouyi Pharmaceutical Company Information
13.15.2 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.15.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cspc Ouyi Pharmaceutical Main Business Overview
13.15.5 Cspc Ouyi Pharmaceutical Latest Developments
13.16 Zhejiang Hisun Pharmaceutical
13.16.1 Zhejiang Hisun Pharmaceutical Company Information
13.16.2 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.16.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhejiang Hisun Pharmaceutical Main Business Overview
13.16.5 Zhejiang Hisun Pharmaceutical Latest Developments
13.17 Hansoh Pharma
13.17.1 Hansoh Pharma Company Information
13.17.2 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.17.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hansoh Pharma Main Business Overview
13.17.5 Hansoh Pharma Latest Developments
13.18 Huahai Pharmaceutical
13.18.1 Huahai Pharmaceutical Company Information
13.18.2 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.18.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Huahai Pharmaceutical Main Business Overview
13.18.5 Huahai Pharmaceutical Latest Developments
13.19 Yangtze River Pharmaceutical
13.19.1 Yangtze River Pharmaceutical Company Information
13.19.2 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.19.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Yangtze River Pharmaceutical Main Business Overview
13.19.5 Yangtze River Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Oral Factor Xa Inhibitors Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Oral Factor Xa Inhibitors by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Oral Factor Xa Inhibitors by Country/Region, 2021, 2025 & 2032
2.2 Oral Factor Xa Inhibitors Segment by Type
2.2.1 Rivaroxaban
2.2.2 Edoxaban
2.2.3 Apixaban
2.2.4 Oral Factor Xa Inhibitors Sales by Type
2.2.4.1 Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
2.2.4.2 Global Oral Factor Xa Inhibitors Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Oral Factor Xa Inhibitors Sale Price by Type (2021-2026)
2.3 Oral Factor Xa Inhibitors Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Oral Factor Xa Inhibitors Sales by Application
2.3.5.1 Global Oral Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
2.3.5.2 Global Oral Factor Xa Inhibitors Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Oral Factor Xa Inhibitors Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Oral Factor Xa Inhibitors Breakdown Data by Company
3.1.1 Global Oral Factor Xa Inhibitors Annual Sales by Company (2021-2026)
3.1.2 Global Oral Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
3.2 Global Oral Factor Xa Inhibitors Annual Revenue by Company (2021-2026)
3.2.1 Global Oral Factor Xa Inhibitors Revenue by Company (2021-2026)
3.2.2 Global Oral Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
3.3 Global Oral Factor Xa Inhibitors Sale Price by Company
3.4 Key Manufacturers Oral Factor Xa Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oral Factor Xa Inhibitors Product Location Distribution
3.4.2 Players Oral Factor Xa Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORAL FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
4.1 World Historic Oral Factor Xa Inhibitors Market Size by Geographic Region (2021-2026)
4.1.1 Global Oral Factor Xa Inhibitors Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Oral Factor Xa Inhibitors Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Oral Factor Xa Inhibitors Market Size by Country/Region (2021-2026)
4.2.1 Global Oral Factor Xa Inhibitors Annual Sales by Country/Region (2021-2026)
4.2.2 Global Oral Factor Xa Inhibitors Annual Revenue by Country/Region (2021-2026)
4.3 Americas Oral Factor Xa Inhibitors Sales Growth
4.4 APAC Oral Factor Xa Inhibitors Sales Growth
4.5 Europe Oral Factor Xa Inhibitors Sales Growth
4.6 Middle East & Africa Oral Factor Xa Inhibitors Sales Growth
5 AMERICAS
5.1 Americas Oral Factor Xa Inhibitors Sales by Country
5.1.1 Americas Oral Factor Xa Inhibitors Sales by Country (2021-2026)
5.1.2 Americas Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
5.2 Americas Oral Factor Xa Inhibitors Sales by Type (2021-2026)
5.3 Americas Oral Factor Xa Inhibitors Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oral Factor Xa Inhibitors Sales by Region
6.1.1 APAC Oral Factor Xa Inhibitors Sales by Region (2021-2026)
6.1.2 APAC Oral Factor Xa Inhibitors Revenue by Region (2021-2026)
6.2 APAC Oral Factor Xa Inhibitors Sales by Type (2021-2026)
6.3 APAC Oral Factor Xa Inhibitors Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Oral Factor Xa Inhibitors by Country
7.1.1 Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026)
7.1.2 Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
7.2 Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026)
7.3 Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Oral Factor Xa Inhibitors by Country
8.1.1 Middle East & Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026)
8.1.2 Middle East & Africa Oral Factor Xa Inhibitors Revenue by Country (2021-2026)
8.2 Middle East & Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026)
8.3 Middle East & Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oral Factor Xa Inhibitors
10.3 Manufacturing Process Analysis of Oral Factor Xa Inhibitors
10.4 Industry Chain Structure of Oral Factor Xa Inhibitors
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oral Factor Xa Inhibitors Distributors
11.3 Oral Factor Xa Inhibitors Customer
12 WORLD FORECAST REVIEW FOR ORAL FACTOR XA INHIBITORS BY GEOGRAPHIC REGION
12.1 Global Oral Factor Xa Inhibitors Market Size Forecast by Region
12.1.1 Global Oral Factor Xa Inhibitors Forecast by Region (2027-2032)
12.1.2 Global Oral Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Oral Factor Xa Inhibitors Forecast by Type (2027-2032)
12.7 Global Oral Factor Xa Inhibitors Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.1.3 Pfizer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Bristol Myers Squibb
13.2.1 Bristol Myers Squibb Company Information
13.2.2 Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.2.3 Bristol Myers Squibb Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bristol Myers Squibb Main Business Overview
13.2.5 Bristol Myers Squibb Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.5.3 Bayer Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Mylan
13.6.1 Mylan Company Information
13.6.2 Mylan Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.6.3 Mylan Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Mylan Main Business Overview
13.6.5 Mylan Latest Developments
13.7 Zydus
13.7.1 Zydus Company Information
13.7.2 Zydus Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.7.3 Zydus Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zydus Main Business Overview
13.7.5 Zydus Latest Developments
13.8 Lupin
13.8.1 Lupin Company Information
13.8.2 Lupin Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.8.3 Lupin Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Lupin Main Business Overview
13.8.5 Lupin Latest Developments
13.9 Apotex
13.9.1 Apotex Company Information
13.9.2 Apotex Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.9.3 Apotex Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Apotex Main Business Overview
13.9.5 Apotex Latest Developments
13.10 Accord Healthcare
13.10.1 Accord Healthcare Company Information
13.10.2 Accord Healthcare Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.10.3 Accord Healthcare Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Accord Healthcare Main Business Overview
13.10.5 Accord Healthcare Latest Developments
13.11 Chia Tai Tianqing Pharmaceutical
13.11.1 Chia Tai Tianqing Pharmaceutical Company Information
13.11.2 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.11.3 Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Chia Tai Tianqing Pharmaceutical Main Business Overview
13.11.5 Chia Tai Tianqing Pharmaceutical Latest Developments
13.12 Shanghai Huilun Pharmaceutical
13.12.1 Shanghai Huilun Pharmaceutical Company Information
13.12.2 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.12.3 Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Shanghai Huilun Pharmaceutical Main Business Overview
13.12.5 Shanghai Huilun Pharmaceutical Latest Developments
13.13 Qilu Pharmaceutical
13.13.1 Qilu Pharmaceutical Company Information
13.13.2 Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.13.3 Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Qilu Pharmaceutical Main Business Overview
13.13.5 Qilu Pharmaceutical Latest Developments
13.14 HEC Pharma
13.14.1 HEC Pharma Company Information
13.14.2 HEC Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.14.3 HEC Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 HEC Pharma Main Business Overview
13.14.5 HEC Pharma Latest Developments
13.15 Cspc Ouyi Pharmaceutical
13.15.1 Cspc Ouyi Pharmaceutical Company Information
13.15.2 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.15.3 Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Cspc Ouyi Pharmaceutical Main Business Overview
13.15.5 Cspc Ouyi Pharmaceutical Latest Developments
13.16 Zhejiang Hisun Pharmaceutical
13.16.1 Zhejiang Hisun Pharmaceutical Company Information
13.16.2 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.16.3 Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Zhejiang Hisun Pharmaceutical Main Business Overview
13.16.5 Zhejiang Hisun Pharmaceutical Latest Developments
13.17 Hansoh Pharma
13.17.1 Hansoh Pharma Company Information
13.17.2 Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.17.3 Hansoh Pharma Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.17.4 Hansoh Pharma Main Business Overview
13.17.5 Hansoh Pharma Latest Developments
13.18 Huahai Pharmaceutical
13.18.1 Huahai Pharmaceutical Company Information
13.18.2 Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.18.3 Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.18.4 Huahai Pharmaceutical Main Business Overview
13.18.5 Huahai Pharmaceutical Latest Developments
13.19 Yangtze River Pharmaceutical
13.19.1 Yangtze River Pharmaceutical Company Information
13.19.2 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
13.19.3 Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
13.19.4 Yangtze River Pharmaceutical Main Business Overview
13.19.5 Yangtze River Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Oral Factor Xa Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Oral Factor Xa Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rivaroxaban
Table 4. Major Players of Edoxaban
Table 5. Major Players of Apixaban
Table 6. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global Oral Factor Xa Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Oral Factor Xa Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global Oral Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global Oral Factor Xa Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Oral Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global Oral Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global Oral Factor Xa Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Oral Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global Oral Factor Xa Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Oral Factor Xa Inhibitors Producing Area Distribution and Sales Area
Table 22. Players Oral Factor Xa Inhibitors Products Offered
Table 23. Oral Factor Xa Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Oral Factor Xa Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Oral Factor Xa Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global Oral Factor Xa Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Oral Factor Xa Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Oral Factor Xa Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global Oral Factor Xa Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Oral Factor Xa Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC Oral Factor Xa Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Oral Factor Xa Inhibitors
Table 53. Key Market Challenges & Risks of Oral Factor Xa Inhibitors
Table 54. Key Industry Trends of Oral Factor Xa Inhibitors
Table 55. Oral Factor Xa Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Oral Factor Xa Inhibitors Distributors List
Table 58. Oral Factor Xa Inhibitors Customer List
Table 59. Global Oral Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Oral Factor Xa Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Oral Factor Xa Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Oral Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Oral Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Oral Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Oral Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Oral Factor Xa Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Oral Factor Xa Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Oral Factor Xa Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Oral Factor Xa Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Pfizer Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 75. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Bristol Myers Squibb Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 80. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Bristol Myers Squibb Main Business
Table 82. Bristol Myers Squibb Latest Developments
Table 83. Daiichi Sankyo Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 85. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Daiichi Sankyo Main Business
Table 87. Daiichi Sankyo Latest Developments
Table 88. Janssen Pharmaceuticals Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 90. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Janssen Pharmaceuticals Main Business
Table 92. Janssen Pharmaceuticals Latest Developments
Table 93. Bayer Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. Bayer Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 95. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Bayer Main Business
Table 97. Bayer Latest Developments
Table 98. Mylan Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Mylan Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 100. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Mylan Main Business
Table 102. Mylan Latest Developments
Table 103. Zydus Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Zydus Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 105. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Zydus Main Business
Table 107. Zydus Latest Developments
Table 108. Lupin Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Lupin Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 110. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Lupin Main Business
Table 112. Lupin Latest Developments
Table 113. Apotex Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Apotex Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 115. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Apotex Main Business
Table 117. Apotex Latest Developments
Table 118. Accord Healthcare Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 120. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Accord Healthcare Main Business
Table 122. Accord Healthcare Latest Developments
Table 123. Chia Tai Tianqing Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 124. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 125. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Chia Tai Tianqing Pharmaceutical Main Business
Table 127. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 128. Shanghai Huilun Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 129. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 130. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Shanghai Huilun Pharmaceutical Main Business
Table 132. Shanghai Huilun Pharmaceutical Latest Developments
Table 133. Qilu Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 134. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 135. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Qilu Pharmaceutical Main Business
Table 137. Qilu Pharmaceutical Latest Developments
Table 138. HEC Pharma Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 139. HEC Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 140. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. HEC Pharma Main Business
Table 142. HEC Pharma Latest Developments
Table 143. Cspc Ouyi Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 144. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 145. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cspc Ouyi Pharmaceutical Main Business
Table 147. Cspc Ouyi Pharmaceutical Latest Developments
Table 148. Zhejiang Hisun Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 149. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 150. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Zhejiang Hisun Pharmaceutical Main Business
Table 152. Zhejiang Hisun Pharmaceutical Latest Developments
Table 153. Hansoh Pharma Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 154. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 155. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Hansoh Pharma Main Business
Table 157. Hansoh Pharma Latest Developments
Table 158. Huahai Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 159. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 160. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Huahai Pharmaceutical Main Business
Table 162. Huahai Pharmaceutical Latest Developments
Table 163. Yangtze River Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 164. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 165. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Yangtze River Pharmaceutical Main Business
Table 167. Yangtze River Pharmaceutical Latest Developments
Table 1. Oral Factor Xa Inhibitors Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Oral Factor Xa Inhibitors Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rivaroxaban
Table 4. Major Players of Edoxaban
Table 5. Major Players of Apixaban
Table 6. Global Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 7. Global Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Table 8. Global Oral Factor Xa Inhibitors Revenue by Type (2021-2026) & ($ million)
Table 9. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Table 10. Global Oral Factor Xa Inhibitors Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Global Oral Factor Xa Inhibitors Sale by Application (2021-2026) & (K Units)
Table 12. Global Oral Factor Xa Inhibitors Sale Market Share by Application (2021-2026)
Table 13. Global Oral Factor Xa Inhibitors Revenue by Application (2021-2026) & ($ million)
Table 14. Global Oral Factor Xa Inhibitors Revenue Market Share by Application (2021-2026)
Table 15. Global Oral Factor Xa Inhibitors Sale Price by Application (2021-2026) & (US$/Unit)
Table 16. Global Oral Factor Xa Inhibitors Sales by Company (2021-2026) & (K Units)
Table 17. Global Oral Factor Xa Inhibitors Sales Market Share by Company (2021-2026)
Table 18. Global Oral Factor Xa Inhibitors Revenue by Company (2021-2026) & ($ millions)
Table 19. Global Oral Factor Xa Inhibitors Revenue Market Share by Company (2021-2026)
Table 20. Global Oral Factor Xa Inhibitors Sale Price by Company (2021-2026) & (US$/Unit)
Table 21. Key Manufacturers Oral Factor Xa Inhibitors Producing Area Distribution and Sales Area
Table 22. Players Oral Factor Xa Inhibitors Products Offered
Table 23. Oral Factor Xa Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Oral Factor Xa Inhibitors Sales by Geographic Region (2021-2026) & (K Units)
Table 27. Global Oral Factor Xa Inhibitors Sales Market Share Geographic Region (2021-2026)
Table 28. Global Oral Factor Xa Inhibitors Revenue by Geographic Region (2021-2026) & ($ millions)
Table 29. Global Oral Factor Xa Inhibitors Revenue Market Share by Geographic Region (2021-2026)
Table 30. Global Oral Factor Xa Inhibitors Sales by Country/Region (2021-2026) & (K Units)
Table 31. Global Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2021-2026)
Table 32. Global Oral Factor Xa Inhibitors Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Oral Factor Xa Inhibitors Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 35. Americas Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Table 36. Americas Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 37. Americas Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 38. Americas Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 39. APAC Oral Factor Xa Inhibitors Sales by Region (2021-2026) & (K Units)
Table 40. APAC Oral Factor Xa Inhibitors Sales Market Share by Region (2021-2026)
Table 41. APAC Oral Factor Xa Inhibitors Revenue by Region (2021-2026) & ($ millions)
Table 42. APAC Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 43. APAC Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 44. Europe Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 45. Europe Oral Factor Xa Inhibitors Revenue by Country (2021-2026) & ($ millions)
Table 46. Europe Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 47. Europe Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 48. Middle East & Africa Oral Factor Xa Inhibitors Sales by Country (2021-2026) & (K Units)
Table 49. Middle East & Africa Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Table 50. Middle East & Africa Oral Factor Xa Inhibitors Sales by Type (2021-2026) & (K Units)
Table 51. Middle East & Africa Oral Factor Xa Inhibitors Sales by Application (2021-2026) & (K Units)
Table 52. Key Market Drivers & Growth Opportunities of Oral Factor Xa Inhibitors
Table 53. Key Market Challenges & Risks of Oral Factor Xa Inhibitors
Table 54. Key Industry Trends of Oral Factor Xa Inhibitors
Table 55. Oral Factor Xa Inhibitors Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Oral Factor Xa Inhibitors Distributors List
Table 58. Oral Factor Xa Inhibitors Customer List
Table 59. Global Oral Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 60. Global Oral Factor Xa Inhibitors Revenue Forecast by Region (2027-2032) & ($ millions)
Table 61. Americas Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 62. Americas Oral Factor Xa Inhibitors Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 63. APAC Oral Factor Xa Inhibitors Sales Forecast by Region (2027-2032) & (K Units)
Table 64. APAC Oral Factor Xa Inhibitors Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 65. Europe Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 66. Europe Oral Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 67. Middle East & Africa Oral Factor Xa Inhibitors Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Middle East & Africa Oral Factor Xa Inhibitors Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Global Oral Factor Xa Inhibitors Sales Forecast by Type (2027-2032) & (K Units)
Table 70. Global Oral Factor Xa Inhibitors Revenue Forecast by Type (2027-2032) & ($ millions)
Table 71. Global Oral Factor Xa Inhibitors Sales Forecast by Application (2027-2032) & (K Units)
Table 72. Global Oral Factor Xa Inhibitors Revenue Forecast by Application (2027-2032) & ($ millions)
Table 73. Pfizer Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 74. Pfizer Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 75. Pfizer Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 76. Pfizer Main Business
Table 77. Pfizer Latest Developments
Table 78. Bristol Myers Squibb Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 79. Bristol Myers Squibb Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 80. Bristol Myers Squibb Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 81. Bristol Myers Squibb Main Business
Table 82. Bristol Myers Squibb Latest Developments
Table 83. Daiichi Sankyo Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 84. Daiichi Sankyo Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 85. Daiichi Sankyo Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 86. Daiichi Sankyo Main Business
Table 87. Daiichi Sankyo Latest Developments
Table 88. Janssen Pharmaceuticals Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 89. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 90. Janssen Pharmaceuticals Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. Janssen Pharmaceuticals Main Business
Table 92. Janssen Pharmaceuticals Latest Developments
Table 93. Bayer Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 94. Bayer Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 95. Bayer Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Bayer Main Business
Table 97. Bayer Latest Developments
Table 98. Mylan Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 99. Mylan Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 100. Mylan Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 101. Mylan Main Business
Table 102. Mylan Latest Developments
Table 103. Zydus Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 104. Zydus Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 105. Zydus Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 106. Zydus Main Business
Table 107. Zydus Latest Developments
Table 108. Lupin Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 109. Lupin Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 110. Lupin Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 111. Lupin Main Business
Table 112. Lupin Latest Developments
Table 113. Apotex Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 114. Apotex Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 115. Apotex Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 116. Apotex Main Business
Table 117. Apotex Latest Developments
Table 118. Accord Healthcare Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 119. Accord Healthcare Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 120. Accord Healthcare Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 121. Accord Healthcare Main Business
Table 122. Accord Healthcare Latest Developments
Table 123. Chia Tai Tianqing Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 124. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 125. Chia Tai Tianqing Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 126. Chia Tai Tianqing Pharmaceutical Main Business
Table 127. Chia Tai Tianqing Pharmaceutical Latest Developments
Table 128. Shanghai Huilun Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 129. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 130. Shanghai Huilun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 131. Shanghai Huilun Pharmaceutical Main Business
Table 132. Shanghai Huilun Pharmaceutical Latest Developments
Table 133. Qilu Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 134. Qilu Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 135. Qilu Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 136. Qilu Pharmaceutical Main Business
Table 137. Qilu Pharmaceutical Latest Developments
Table 138. HEC Pharma Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 139. HEC Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 140. HEC Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 141. HEC Pharma Main Business
Table 142. HEC Pharma Latest Developments
Table 143. Cspc Ouyi Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 144. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 145. Cspc Ouyi Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 146. Cspc Ouyi Pharmaceutical Main Business
Table 147. Cspc Ouyi Pharmaceutical Latest Developments
Table 148. Zhejiang Hisun Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 149. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 150. Zhejiang Hisun Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 151. Zhejiang Hisun Pharmaceutical Main Business
Table 152. Zhejiang Hisun Pharmaceutical Latest Developments
Table 153. Hansoh Pharma Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 154. Hansoh Pharma Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 155. Hansoh Pharma Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 156. Hansoh Pharma Main Business
Table 157. Hansoh Pharma Latest Developments
Table 158. Huahai Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 159. Huahai Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 160. Huahai Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 161. Huahai Pharmaceutical Main Business
Table 162. Huahai Pharmaceutical Latest Developments
Table 163. Yangtze River Pharmaceutical Basic Information, Oral Factor Xa Inhibitors Manufacturing Base, Sales Area and Its Competitors
Table 164. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Product Portfolios and Specifications
Table 165. Yangtze River Pharmaceutical Oral Factor Xa Inhibitors Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 166. Yangtze River Pharmaceutical Main Business
Table 167. Yangtze River Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Oral Factor Xa Inhibitors
Figure 2. Oral Factor Xa Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Factor Xa Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Oral Factor Xa Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Oral Factor Xa Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rivaroxaban
Figure 12. Product Picture of Edoxaban
Figure 13. Product Picture of Apixaban
Figure 14. Global Oral Factor Xa Inhibitors Sales Market Share by Type in 2026
Figure 15. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. Oral Factor Xa Inhibitors Consumed in Deep Vein Thrombosis
Figure 17. Global Oral Factor Xa Inhibitors Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 18. Oral Factor Xa Inhibitors Consumed in Pulmonary Embolism
Figure 19. Global Oral Factor Xa Inhibitors Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 20. Oral Factor Xa Inhibitors Consumed in Atrial Fibrillation
Figure 21. Global Oral Factor Xa Inhibitors Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 22. Oral Factor Xa Inhibitors Consumed in Other
Figure 23. Global Oral Factor Xa Inhibitors Market: Other (2021-2026) & (K Units)
Figure 24. Global Oral Factor Xa Inhibitors Sale Market Share by Application (2025)
Figure 25. Global Oral Factor Xa Inhibitors Revenue Market Share by Application in 2026
Figure 26. Oral Factor Xa Inhibitors Sales by Company in 2026 (K Units)
Figure 27. Global Oral Factor Xa Inhibitors Sales Market Share by Company in 2026
Figure 28. Oral Factor Xa Inhibitors Revenue by Company in 2026 ($ millions)
Figure 29. Global Oral Factor Xa Inhibitors Revenue Market Share by Company in 2026
Figure 30. Global Oral Factor Xa Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Oral Factor Xa Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 33. Americas Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. APAC Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 35. APAC Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Europe Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 37. Europe Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 40. Americas Oral Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 41. Americas Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 42. Americas Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 43. Americas Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 44. United States Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Oral Factor Xa Inhibitors Sales Market Share by Region in 2026
Figure 49. APAC Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2026)
Figure 50. APAC Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 51. APAC Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 52. China Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. India Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Oral Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 60. Europe Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 61. Europe Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 62. Europe Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 63. Germany Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. France Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 71. Egypt Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Oral Factor Xa Inhibitors in 2026
Figure 77. Manufacturing Process Analysis of Oral Factor Xa Inhibitors
Figure 78. Industry Chain Structure of Oral Factor Xa Inhibitors
Figure 79. Channels of Distribution
Figure 80. Global Oral Factor Xa Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 81. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Oral Factor Xa Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Oral Factor Xa Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Oral Factor Xa Inhibitors
Figure 2. Oral Factor Xa Inhibitors Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Oral Factor Xa Inhibitors Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Oral Factor Xa Inhibitors Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Oral Factor Xa Inhibitors Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2025)
Figure 10. Oral Factor Xa Inhibitors Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rivaroxaban
Figure 12. Product Picture of Edoxaban
Figure 13. Product Picture of Apixaban
Figure 14. Global Oral Factor Xa Inhibitors Sales Market Share by Type in 2026
Figure 15. Global Oral Factor Xa Inhibitors Revenue Market Share by Type (2021-2026)
Figure 16. Oral Factor Xa Inhibitors Consumed in Deep Vein Thrombosis
Figure 17. Global Oral Factor Xa Inhibitors Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 18. Oral Factor Xa Inhibitors Consumed in Pulmonary Embolism
Figure 19. Global Oral Factor Xa Inhibitors Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 20. Oral Factor Xa Inhibitors Consumed in Atrial Fibrillation
Figure 21. Global Oral Factor Xa Inhibitors Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 22. Oral Factor Xa Inhibitors Consumed in Other
Figure 23. Global Oral Factor Xa Inhibitors Market: Other (2021-2026) & (K Units)
Figure 24. Global Oral Factor Xa Inhibitors Sale Market Share by Application (2025)
Figure 25. Global Oral Factor Xa Inhibitors Revenue Market Share by Application in 2026
Figure 26. Oral Factor Xa Inhibitors Sales by Company in 2026 (K Units)
Figure 27. Global Oral Factor Xa Inhibitors Sales Market Share by Company in 2026
Figure 28. Oral Factor Xa Inhibitors Revenue by Company in 2026 ($ millions)
Figure 29. Global Oral Factor Xa Inhibitors Revenue Market Share by Company in 2026
Figure 30. Global Oral Factor Xa Inhibitors Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Oral Factor Xa Inhibitors Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 33. Americas Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 34. APAC Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 35. APAC Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 36. Europe Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 37. Europe Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Oral Factor Xa Inhibitors Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Oral Factor Xa Inhibitors Revenue 2021-2026 ($ millions)
Figure 40. Americas Oral Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 41. Americas Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 42. Americas Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 43. Americas Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 44. United States Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Oral Factor Xa Inhibitors Sales Market Share by Region in 2026
Figure 49. APAC Oral Factor Xa Inhibitors Revenue Market Share by Region (2021-2026)
Figure 50. APAC Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 51. APAC Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 52. China Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 56. India Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Oral Factor Xa Inhibitors Sales Market Share by Country in 2026
Figure 60. Europe Oral Factor Xa Inhibitors Revenue Market Share by Country (2021-2026)
Figure 61. Europe Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 62. Europe Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 63. Germany Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 64. France Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Oral Factor Xa Inhibitors Sales Market Share by Application (2021-2026)
Figure 71. Egypt Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Oral Factor Xa Inhibitors Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Oral Factor Xa Inhibitors in 2026
Figure 77. Manufacturing Process Analysis of Oral Factor Xa Inhibitors
Figure 78. Industry Chain Structure of Oral Factor Xa Inhibitors
Figure 79. Channels of Distribution
Figure 80. Global Oral Factor Xa Inhibitors Sales Market Forecast by Region (2027-2032)
Figure 81. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Oral Factor Xa Inhibitors Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Oral Factor Xa Inhibitors Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Oral Factor Xa Inhibitors Revenue Market Share Forecast by Application (2027-2032)
